DERTSCHNIG, Simone, FINKE, Jürgen, HEIM, Dominik, SCHANZ, Urs, HOLLER, Ernst, HOLTICK, Udo, SOCIÉ, Gerard, TESHIMA, Takanori, BUCHER, Christoph und PASSWEG, Jakob R., 2024. S235: A two-part, single- and two-arm randomized, open-label study to evaluate the safety, tolerability and pharmacokinetics of the S1 P receptor modulator KRP203 in subjects with hematological malignancies. Freiburg: Universität.

Dertschnig, S., Finke, J., Heim, D., Schanz, U., Holler, E., Holtick, U., Socié, G., Teshima, T., Bucher, C., Passweg, J.R., 2024. S235: A two-part, single- and two-arm randomized, open-label study to evaluate the safety, tolerability and pharmacokinetics of the S1 P receptor modulator KRP203 in subjects with hematological malignancies. Universität, Freiburg. https://doi.org/10.1097/01.hs9.0000843832.53729.72

Dertschnig, S., Finke, J., Heim, D., Schanz, U., Holler, E., Holtick, U., Socié, G., Teshima, T., Bucher, C., & Passweg, J. R. (ca. 2024). S235: A two-part, single- and two-arm randomized, open-label study to evaluate the safety, tolerability and pharmacokinetics of the S1 P receptor modulator KRP203 in subjects with hematological malignancies [Cd]. Universität. https://doi.org/10.1097/01.hs9.0000843832.53729.72

Dertschnig S, Finke J, Heim D, Schanz U, Holler E, Holtick U, Socié G, Teshima T, Bucher C, Passweg JR (2024) S235: A two-part, single- and two-arm randomized, open-label study to evaluate the safety, tolerability and pharmacokinetics of the S1 P receptor modulator KRP203 in subjects with hematological malignancies. Universität, Freiburg

Dertschnig, Simone/ Finke, Jürgen/ Heim, Dominik/ Schanz, Urs/ Holler, Ernst/ Holtick, Udo/ Socié, Gerard/ Teshima, Takanori/ Bucher, Christoph/ Passweg, Jakob R., S235: A two-part, single- and two-arm randomized, open-label study to evaluate the safety, tolerability and pharmacokinetics of the S1 P receptor modulator KRP203 in subjects with hematological malignancies, Freiburg 2024.